Ranolazine
- Product NDC
- 43975-289
- 11-digit product format
- 439750289
- Labeler code
- 43975
- Product ID
- 43975-289_5d37b8e0-3e6d-4ea3-9d98-4d6faa1c7f02
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Ranolazine
- Dosage form
- TABLET, EXTENDED RELEASE
- Route
- ORAL
- Labeler
- ANI Pharmaceuticals, Inc.
- Application
- ANDA210482
- Marketing category
- ANDA
- Marketing start
- 2020-01-23
- Marketing end
- 2021-11-30
- Substance
- RANOLAZINE
- Active strength
- 1 g/1
- Pharmacologic classes
- Anti-anginal [EPC],Cytochrome P450 3A Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Organic Cation Transporter 2 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 0000-00-00
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 43975-289-06 | 43975028906 | 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (43975-289-06) | 2020-01-23 | 2021-11-30 | No | No | Current |